{
    "clinical_study": {
        "@rank": "30029", 
        "arm_group": [
            {
                "arm_group_label": "C Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes"
            }, 
            {
                "arm_group_label": "E Group", 
                "arm_group_type": "Experimental", 
                "description": "Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "1. To observe clinical and bacteriologic responses of different regimens of\n           piperacillin/tazobactam (4.5g q6h, prolonged or intermittent infusion) for treatment of\n           nosocomial pneumonia.\n\n        2. To describe the pharmacokinetic profile of piperacillin/tazobactam (4.5g q6h, prolonged\n           or intermittent infusion) in patients with nosocomial pneumonia.\n\n        3. To assess the safety profiles of piperacillin/tazobactam 4.5g q6h, prolonged or\n           intermittent infusion in patients with nosocomial pneumonia."
        }, 
        "brief_title": "Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Nosocomial Pneumonia", 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "detailed_description": {
            "textblock": "Enrolled patients will be randomized into therapeutic or controlled group. Controlled group\n      will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes.\n      Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4\n      hours. The duration is 7-14 days.\n\n      Two sets of blood cultures (for aerobic and anaerobic culture) were obtained before the\n      study and post-treatment period if first blood culture is positive. Cultures from the lower\n      respiratory tract infection were obtained before (within 48 h) the study and on the last day\n      of therapy. The lower respiratory tract specimens obtained either by endotracheal\n      aspiration, bronchoalveolar lavage (BAL), a protected brush procedure (PBP) or as sputum\n      were required to show > 25 polymorphonuclear cells and < 10 squamous epithelial cells per\n      field (at 100\u00d7 magnification).\n\n      The plasma concentration of piperacillin and tazobactam will be determined by LC/MS/MS\n      method. The QC samples will also be analyzed simultaneously with each run for the method\n      stability testing, according to the laboratory standard procedure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female, aged 18 to 70 years old.\n\n          2. Inpatients with nosocomial pneumonia or bacteremia.\n\n             i. Diagnosis of nosocomial pneumonia\n\n               1. Chest radiographic infiltrate that is new or progressive.\n\n               2. At least two or more of the following clinical findings suggesting infection.\n\n                    -  New onset of fever, oral temperature T>38.3\u2103 or T<36\u2103\n\n                         -  Purulent sputum\n\n                              -  WBC > 12\u00d710^9/L or <4\u00d710^9/L, or band form >10%\n\n                                   -  PaO2/FIO2<240mmHg\n\n             ii. Diagnosis of bacteremia: Positive blood culture and the isolated bacterial strain\n             are considered to be infection cause.\n\n          3. Patients are infected by piperacillin-tazobactam susceptible pathogen with MIC=4, 8\n             or 16mg/L.\n\n        Exclusion Criteria:\n\n          1. The patients who received systematic antibacterial treatment more than 48 hours\n             before enrollment and have clinical response.\n\n          2. Severe pyemia with hypotension or/and evidences of failure of organic function\n             (shock: systolic pressure < 90mmHg or diastolic pressure < 60mmHg, requiring more\n             than 4 hours of administration of vasopressor(s)\uff1brenal impairment: urine volume < 20\n             ml\u2215h or < 80 ml\u22154h after excluded any other potentials, acute renal failure need\n             dialysis, CLcr<40 mL/min).\n\n          3. Documented infection caused by pathogens beyond the antibacterial spectrum of\n             piperacillin/tazobactam.\n\n          4. Previously diagnosed condition which tend to mimic or complicate the course and\n             evaluation of the infectious process, e.g. bronchial obstruction, obstructive\n             pneumonia, activate pulmonary malignancy, pulmonary abscess, empyema and active\n             tuberculosis, which might interfere the course of the infectious disease and\n             evaluation of the disease.\n\n          5. History of allergy to penicillins.\n\n          6. Pregnancy or breast-feeding women.\n\n          7. Any conditions investigator considered might increase the risk of patients or\n             interfere study results."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796717", 
            "org_study_id": "CIH-WDH-201205001"
        }, 
        "intervention": [
            {
                "arm_group_label": "C Group", 
                "description": "Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes", 
                "intervention_name": "C Group", 
                "intervention_type": "Drug", 
                "other_name": [
                    "nosocomial pneumonia", 
                    "MIC"
                ]
            }, 
            {
                "arm_group_label": "E Group", 
                "description": "Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours", 
                "intervention_name": "E Group", 
                "intervention_type": "Drug", 
                "other_name": [
                    "nosocomial pneumonia", 
                    "MIC"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Piperacillin", 
                "Penicillanic Acid", 
                "Piperacillin-tazobactam combination product", 
                "Tazobactam"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Piperacillin/tazobactam", 
            "MIC"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": [
            {
                "contact": {
                    "email": "donghaow@medmail.com.cn", 
                    "last_name": "Wang Donghao, Chief", 
                    "phone": "022-23340123", 
                    "phone_ext": "1021"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300060"
                    }, 
                    "name": "TianjinCIH"
                }, 
                "investigator": [
                    {
                        "last_name": "Yang Yang, resident", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "lv yang, resident", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "donghaow@medmail.com.cn", 
                    "last_name": "Wang Donghao, Chief", 
                    "phone": "022-23340123", 
                    "phone_ext": "1021"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin", 
                        "zip": "300060"
                    }, 
                    "name": "TianjinCIH"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Optimizing Dosing Regimen of Piperacillin/Tazobactam, Prolonged Infusion vs. Regular Infusion, Every 6 Hours, for Nosocomial Pneumonia in ICU Caused by Susceptible Pathogens With Higher MIC", 
        "overall_contact": {
            "email": "donghaow@medmail.com.cn", 
            "last_name": "Wang Donghao, chief", 
            "phone": "022-23340123", 
            "phone_ext": "1021"
        }, 
        "overall_official": {
            "affiliation": "Tianjin Medical University Cancer Institute and Hospital", 
            "last_name": "Wang Donghao, Chief", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To observe clinical and bacteriologic responses of different regimens of piperacillin/tazobactam (4.5g q6h, prolonged or intermittent infusion) for treatment of nosocomial pneumonia.", 
            "measure": "Extension of the Piperacillin / tazobactam infusion time effect evaluation", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "reference": [
            {
                "PMID": "20018492", 
                "citation": "Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents. 2010 Feb;35(2):156-63. doi: 10.1016/j.ijantimicag.2009.10.008. Epub 2009 Dec 16."
            }, 
            {
                "PMID": "20047820", 
                "citation": "Wang H, Chen M, Ni Y, Liu Y, Sun H, Yu Y, Yu X, Mei Y, Liu M, Sun Z, Chu Y, Hu Z, Huang X. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int J Antimicrob Agents. 2010 Mar;35(3):227-34. doi: 10.1016/j.ijantimicag.2009.11.010. Epub 2010 Jan 4."
            }, 
            {
                "PMID": "19150225", 
                "citation": "Lorente L, Jim\u00e9nez A, Mart\u00edn MM, Iribarren JL, Jim\u00e9nez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents. 2009 May;33(5):464-8. doi: 10.1016/j.ijantimicag.2008.10.025. Epub 2009 Jan 15."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796717"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To describe the pharmacokinetic profile of piperacillin/tazobactam (4.5g q6h, prolonged or intermittent infusion) in patients with nosocomial pneumonia.", 
            "measure": "Reducing antibiotic resistance", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "source": "Tianjin Medical University Cancer Institute and Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Tianjin Medical University Cancer Institute and Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}